Galantamine Hydrobromide

CAT:
400-SIH-530-20MG
Size:
20 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Galantamine Hydrobromide - image 1
Galantamine Hydrobromide - image 2
Thumbnail 1
Thumbnail 2

Galantamine Hydrobromide

  • Background:

    Galantamine hydrobromide is a long-acting, active acetylcholinesterase inhibitor (IC50 = 410 nM) and allosteric potentiator at neuronal nicotinic ACh receptors (1,2). It prevents β-amyloid-induced apoptosis in SH-SY5Y (3). Long-term administration in a mouse model of Alzheimer's disease reduces amyloid precursor protein deposition and neurodegeneration in these mice (4,5).
  • Description:

    Cholinesterase Inhibitor
  • Product Name Alternative:

    Galantamine hydrobromide, Galantamine HBr, Galanthamine hydrobromide, Galanthamine, Galanthamine hydrogen bromide, SPECTRUM1501202, 1,2,3,4,6,7,7a,11c-Octahydro-9-methoxy-2-methyl-benzofuro (4,3,2-efg) (2) benzazocin-6-ol HBr, LS-185021, Galanthamine, Nivalin, Reminyl, Jilkon hydrobromide, Lycoremine hydrobromide
  • UNSPSC:

    41116105
  • Type:

    Inhibitor
  • Source:

    Synthetic
  • Field of Research:

    Neuroscience | Neurodegeneration | Alzheimer's Disease | Cancer | Apoptosis
  • Purity:

    >97% (HPLC) ; NMR (Conforms)
  • Weight:

    0.02
  • Format:

    White powder
  • Solubility:

    Soluble in water (12 mg/ml) or in DMSO (10 mg/ml)
  • Molecular Formula:

    C17H22BrNO3
  • Molecular Weight:

    368.3
  • Precautions:

    Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
  • References & Citations:

    1. M Racchi et al. Pharmacol. Res. 2004 50:441 2. M Samochocki et al. J. Pharmacol. Exp. Ther. 2003 305:1024 3. E Arias et al. Neuropharmacology 2004 46:103 4. K Rockwood et al. J. Neurol. Neurosurg. Psychiatry 2001 71:589 5. S Chen et al. Curr. Neuropharmacol. 2007 5:127
  • CAS Number:

    1953-04-4